[July 5, 2021 - Hong Kong] Great Bay Bio Holdings Limited (hereinafter referred to as “GBB”) announces that the company’s self-developed intelligent cell line stability prediction platform AlfaStaX, is officially launched. Given the easy accessibility and high-through put of cell images, AlfaStaX enables to obtain cell images of all cell line candidates which were monitored in sub-culturing process within 15 days by using cutting-edge AI technology with reliable predictive solutions, based on which the stability of the 90th-day cell lines can be predicted. Through obtaining cell line stability information in advance, it will substantially shorten the R&D timeline, and reduce R&D risks and costs up to 80%.

Industry Pain Points

In the process of large-scale production, the cell line is needed to be passaged and amplified for a long time and for multiple times, during which the industrialized cell line have to be ensured to perform stably. Therefore, the stability of cell lines becomes one of the paramount indices to evaluate the quality of cell lines and study of cell line stability is also an indispensable part in the industry.

Cells are needed to be sub-cultured for 90 consecutive days in stability research experiments, which is a labor-intensive and time-consuming step and has become an overarching bottleneck in R&D process. Therefore, the stability research can only be conducted after the process development of a part of ed cell line candidates by R&D scientists. Unfortunately, some instable cell line will be mistakenly passed and some quality candidates will be unintentionally omitted in the whole process.

AlfaStaX^®Values

1. Reduce up to 80% of time and cost of stability research, and accelerate R&D process (from 90 days to 15 days);

2. More candidates available to avoid omitting high-quality cell lines

3. Focus on high-quality cell lines to reduce R&D risks and improve R&D efficiency.

About Great Bay Bio

Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to biopharmaceutical development and other blue ocean bio-products, ultimately solving numerous pain points of biopharmaceutical industry, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3000 m² CMC facilities which bolster advance equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation of AI-enabled bioprocessing ecosystem. To learn more, please visit http://www.greatbay-bio.com.